CervoMed Inc. (CRVO)

CervoMed, Inc.'s stock has experienced significant volatility, declining by 62.71% from May 5, 2025, to May 1, 2026, and trading between $3.51 and $13.13 over the past 52 weeks. Positive clinical data and regulatory alignment for neflamapimod in DLB have created upward pressure, while missed earnings, reporting an EPS of -$0.88, missing the consensus estimate of -$0.79, and quarterly revenue of $0.01 million also falling below analysts' expectations of $0.84 million, and cash runway concerns have negatively impacted the stock. Recent insider buying activity has also been noted.

CervoMed, Inc.'s products and services are not subject to typical demand seasonality. The demand for neflamapimod will primarily be driven by clinical trial progress, regulatory approvals, and market adoption, rather than seasonal fluctuations.

CervoMed, Inc. is a clinical-stage biotechnology company focused on developing treatments for age-related neurological disorders, particularly neurodegenerative diseases like dementia with Lewy bodies (DLB). Their primary product candidate is neflamapimod, an orally administered small molecule drug designed to inhibit the p38α enzyme, aiming to reverse synaptic dysfunction and improve neuron health. The company also has EIP200 in preclinical trials for central nervous system disorders.

CervoMed, Inc. is headquartered in Boston, Massachusetts, United States. Information regarding a broader geographic operational footprint or specific markets beyond its headquarters is not readily available.

CervoMed, Inc.'s brand reputation is influenced by clinical development progress and analyst sentiment. Positive clinical data on neflamapimod and regulatory alignment have contributed positively, as has a "Strong Buy" or "Moderate Buy" consensus rating from analysts. However, the significant stock price decline and cash runway concerns could negatively impact its reputation among investors.

CervoMed, Inc.'s ownership includes institutional, retail, and individual investors. The company has 44 institutional owners holding a total of 2,246,796 shares, including AWM Investment Company, Inc., Morgan Stanley, and Vanguard Group Inc. Individual insiders own approximately 44.05% of the company, with Joshua Boger being the largest shareholder with 13% of shares outstanding.